BioVaxys and Sona Nanotech Collaboration on Cancer Therapeutics
Thursday, May 08, 2025
BioVaxys Technology and Sona Nanotech have entered a research agreement to jointly explore new cancer treatment approaches.
This collaboration will focus on combining BioVaxys’ DPX™ Immune Educating Platform with Sona’s Targeted Hyperthermia Therapy™ (THT), which uses focused infrared light and gold nanorods (GNRs) to treat solid tumours by generating heat and triggering immune responses.
The company is currently preparing for its first human clinical trial using THT and continues to expand its pipeline of potential applications.
The research partnership will assess how the DPX platform, known for its strong immune-stimulating abilities, can enhance the therapeutic effects of THT.
The next stage will involve using DPX as a carrier for novel tumour neoantigens, which may emerge after THT treatment.
Research will be carried out at Dalhousie University in Halifax, Nova Scotia, under the direction of Sona’s Chief Medical Officer and a professor of pathology and surgery, along with the Giacomantonio Immuno-Oncology Research Group. Both BioVaxys and Sona will contribute their technologies to the research, which will be funded by the research group itself.
Any new therapeutic candidates developed through this partnership will be jointly owned and protected by both companies. Plans are already in place to agree on a commercialisation strategy for any resulting vaccine candidate before advancing to a Phase 1 clinical trial.
The technology directs antigens to regional lymph nodes and has demonstrated strong T cell and B cell activation across several clinical and preclinical studies in oncology and infectious diseases.
This collaboration between BioVaxys and Sona aims to combine these complementary technologies to create more effective cancer treatments, particularly for patients whose tumours are resistant to existing immunotherapies.
Source: biovaxys.com
